SGLT2 inhibitors promote glycosuria and a shift toward ketone metabolism, and they have been associated with euglycemic DKA in patients with type 1 and type 2 diabetes [23,24,25]. Here, SLC5A2 is linked to type 2 diabetes mellitus.